Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Microsoft, Lowers Price Target to $300

Citigroup analyst Tyler Radke maintains Microsoft (NASDAQ:MSFT) with a Buy and lowers the price target from $330 to $300.
byBenzinga Newsdesk
July 27, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Tyler Radke maintains Microsoft (NASDAQ:MSFT) with a Buy and lowers the price target from $330 to $300.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Drugs for Neglected Diseases Initiative and Sanofi Announced Treatment Success Rates of Up to 95% From a Phase II/II Study Investigating the Safety and Efficacy of Single-dose Acoziborole for Sleeping Sickness

By Charles Gross
November 30, 5:49 AM
The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal.

SNY